Disclosures: Choueiri reviews honoraria from, advisor/advisory roles with, journey lodging and bills from and/or analysis funding to his establishment from Agensys, Alexion Prescription drugs, Alligent, ASCO, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly & Co., EMD Serono, Exelixis, Basis Medication, Genentech/Roche, GlaxoSmithKline, Janssen Oncology, Merck, Michael J. Hennessy Associates, Sanofi/Aventis, Seagen/Astellas, Takeda and several other different entities exterior the submitted work. Please see the examine for all different authors’ related monetary disclosures.
Cabozantinib routine ‘beat the doublet in PFS’ in untreated superior kidney most cancers
Cabozantinib plus nivolumab and ipilimumab conferred a big PFS profit vs. nivolumab and ipilimumab alone amongst sufferers with superior renal cell carcinoma, in response to outcomes of the COSMIC-313 trial introduced at ESMO Congress.
“COSMIC-313 is the primary part 3 trial utilizing a contemporary doublet management of nivolumab [Opdivo, Bristol Myers Squibb] and ipilimumab [Yervoy, Bristol Myers Squibb] and asking the query of whether or not including cabozantinib [Cabometyx/Cometriq, Exelixis] could result in improved outcomes and optimistic outcomes amongst sufferers with superior renal cell carcinoma,” Toni Ok. Choueiri, MD, director of the Lank Heart for Genitourinary Oncology at Dana-Farber Most cancers Institute and Jerome and Nancy Kohlberg chair and professor of medication at Harvard Medical Faculty, informed Healio.
Knowledge derived from Choueiri TK, et al. Summary LBA8. Introduced at: European Society for Medical Oncology Congress; Sept. 9-13, 2022; Paris.
Toni Ok. Choueiri
The trial included 855 beforehand untreated sufferers with superior renal cell carcinoma at intermediate danger (75%) or poor danger (25%) for survival in response to the Worldwide Metastatic RCC Database Consortium danger mannequin.
PFS by blinded unbiased radiology assessment per RECIST 1.1 among the many first 550 randomly assigned sufferers served as the first endpoint. OS amongst all randomly assigned sufferers served because the secondary endpoint.
Median follow-up was between 17.7 and 20.2 months.
Outcomes confirmed sufferers who obtained cabozantinib, a multitargeted tyrosine kinase inhibitor, plus nivolumab and ipilimumab skilled a 27% decrease danger for illness development or loss of life in contrast with those that obtained nivolumab and ipilimumab alone (median, not reached vs. 11.3 months; HR = 0.73; 95% CI, 0.57-0.94).
PFS amongst subgroups appeared largely in keeping with the first endpoint outcomes, and additional analyses recommended these labeled as intermediate vs. poor danger skilled higher profit with the cabozantinib routine.
Researchers recognized no important survival profit for the three-drug mixture; the OS evaluation is ongoing.
“That is the primary examine in kidney most cancers the place we see the triplet beat the doublet in PFS,” Choueiri stated.
The triplet additionally conferred a numerically greater goal response price (43% vs. 36%) and illness management price (86% vs. 72%) than the doublet, with a usually manageable security profile in keeping with that of every particular person therapy. Choueiri famous greater incidence of treatment-related will increase in alanine aminotransferase (46% vs. 17%) and aspartate aminotransferase (44% vs. 16%), in addition to diarrhea (41% vs. 18%) and pores and skin toxicity, within the cabozantinib vs. management group.
The subsequent steps are to see how one can combine this routine into follow, if authorized by regulatory authorities, Choueiri informed Healio.
“The therapy panorama in kidney most cancers continues to evolve, leading to extra choices for superior illness, however there’s nonetheless a necessity for extra, efficient first-line therapy choices, particularly for sufferers with intermediate- or poor-risk illness. It’s basically discovering the appropriate affected person inhabitants, so we want additional analysis to seek out the subsets of sufferers that can profit,” Choueiri stated.